Ser313
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser313  -  ROMK (human)

Site Information
ATCQVRTsYVPEEVL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2461200

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 2 , 3 )
Relevant cell line - cell type - tissue:
oocyte ( 1 , 2 , 3 )

Upstream Regulation
Treatments:
Levetiracetam ( 3 )

Downstream Regulation
Effects of modification on ROMK:
activity, induced ( 3 ) , activity, inhibited ( 2 ) , protein conformation ( 1 )

References 

1

Lee CH, Huang PT, Lou KL, Liou HH (2008) Functional and structural characterization of PKA-mediated pHi gating of ROMK1 channels. J Mol Graph Model 27, 332-41
18620882   Curated Info

2

Lee CH, et al. (2008) d-Amphetamine inhibits inwardly rectifying potassium channels in Xenopus oocytes expression system. Neurotoxicology 29, 638-46
18571730   Curated Info

3

Lee CH, Lee CY, Tsai TS, Liou HH (2008) PKA-mediated phosphorylation is a novel mechanism for levetiracetam, an antiepileptic drug, activating ROMK1 channels. Biochem Pharmacol 76, 225-35
18547545   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.